ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,989.60
0.00%
S&P ASX All Technology
3,123.90
0.00%
Brent Oil
79.155
-1.76%
US Dollar vs AUD
1.5272
0.08%
Bitcoin
67,330.57
-0.69%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immunic Inc (IMUX)

  7. Immunic Inc (IMUX) News

IMUX

Immunic (IMUX)

Immunic Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMUX
DateTimeSourceHeadlineSymbolCompany
25/07/202406:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
25/07/202406:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
24/07/202420:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
24/07/202420:30PR Newswire (US)Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona SkerjanecNASDAQ:IMUXImmunic Inc
12/07/202422:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
12/07/202422:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
09/07/202420:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
09/07/202420:30PR Newswire (US)Immunic Appoints Jason Tardio as Chief Operating Officer and PresidentNASDAQ:IMUXImmunic Inc
13/06/202406:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
13/06/202406:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
13/06/202406:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
11/06/202406:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMUXImmunic Inc
03/06/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMUXImmunic Inc
28/05/202420:30PR Newswire (US)Immunic to Participate in Industry and Scientific Conferences in JuneNASDAQ:IMUXImmunic Inc
25/05/202406:06Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:IMUXImmunic Inc
08/05/202421:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMUXImmunic Inc
08/05/202420:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
08/05/202420:30PR Newswire (US)Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
06/05/202420:30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in MayNASDAQ:IMUXImmunic Inc
01/05/202420:30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
30/04/202420:30PR Newswire (US)Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationNASDAQ:IMUXImmunic Inc
04/04/202421:30PR Newswire (US)Immunic to Host MS R&D Day and Participate in Investor Conferences in AprilNASDAQ:IMUXImmunic Inc
20/03/202421:30PR Newswire (US)Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United StatesNASDAQ:IMUXImmunic Inc
09/03/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
07/03/202422:30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in MarchNASDAQ:IMUXImmunic Inc
07/03/202413:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
 Showing the most relevant articles for your search:NASDAQ:IMUX

Your Recent History

NYSE
VZ
Verizon Communications
ASX
XAO
Australian SE All Ordina...
ASX
SUN
Suncorp
ASX
NAB
National Australia Bank
ASX
WDC
Westfield
COIN
ETHUSD
Ethereum
NASDAQ
AMZN
Amazon.com
ASX
MQG
Macquarie
ASX
CSL
CSL
NYSE
MCD
McDonalds
ASX
BHP
BHP
ASX
WPL
Woodside Petroleum
NYSE
KO
Coca Cola
FX
AUDUSD
AUD vs US Dollar
ASX
CBA
Commonwealth Bank Of Aus...
ASX
NCM
Newcrest Mining
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved